Results 11 to 20 of about 11,412 (211)

Mid-term survival in patients awaiting heart and kidney transplantation with Impella 5.5 support. [PDF]

ESC Heart Fail
Abstract Background Patients with end‐stage heart failure and chronic kidney disease requiring dual‐organ transplantation (DOT) face significant challenges in utilizing durable mechanical circulatory support due to the risks associated with renal replacement therapies (RRTs) and multi‐organ failure.
Desai S, Paghdar S, Ruiz J, Jang JM, Malkani S, Yip DS, Leoni J, Nativi J, Sareyyupoglu B, Landolfo K, Pham S, Patel P, Goswami R.   +12 more
europepmc   +2 more sources

A case of left ventricular free wall rupture after insertion of an IMPELLA® left ventricular assist device diagnosed by transesophageal echocardiography

JA Clinical Reports, 2021
Background The IMPELLA® is a minimally invasive left ventricular assist device. We report a case in which transesophageal echocardiography (TEE) was useful in diagnosis of left ventricular rupture after IMPELLA® insertion. Case presentation A 75-year-old
Akito Mizuno, Shuji Kawamoto, Shuji Uda, Kenichiro Tatsumi, Chikashi Takeda, Tomoharu Tanaka, Kazuhiko Fukuda   +6 more
doaj   +1 more source

Single center first year experience and outcomes with Impella 5.5 left ventricular assist device

Journal of Cardiothoracic Surgery, 2022
Background The Impella 5.5® was approved by the FDA for use for mechanical circulatory support up to 14 days in late 2019 at limited centers in the United States.
Joanna R. Rock, Cynthia A. Kos, Anthony Lemaire, Hirohisa Ikegami, Mark J. Russo, Danyaal Moin, Kenneth Dulnuan, Deepa Iyer   +7 more
doaj   +1 more source

Extracorporeal membrane oxygenation and microaxial left ventricular assist device in cardiogenic shock: Choosing the right mechanical circulatory support to improve outcomesCentral MessagePerspective

JTCVS Open, 2023
Objective: To evaluate the outcomes of patients supported with Impella (CP/5.0) or venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock according to shock phenotype. The primary end point was 30-day survival.
Olina Dagher, MD, Pierre-Emmanuel Noly, MD, PhD, Walid Ben Ali, MD, PhD, Nadia Bouabdallaoui, MD, PhD, Lucian Geicu, MD, Roxanne Lamanna, Pavan Malhi, BScN, Elizabeth Romero, Anique Ducharme, MD, MSc, Philippe Demers, MD, MSc, Yoan Lamarche, MD, MSc   +10 more
doaj   +1 more source

Impella 5.0 supported oncological surgery as bridge to LVAD

ESC Heart Failure, 2021
We describe the case of a 58‐year‐old man presenting with myocardial infarction complicated by cardiogenic shock, treated with Impella CP which was escalated to an axillary 5.0 due to lack of cardiac recovery.
Andrea Montisci, Giancarlo Micheletto, Serena Sibilio, Francesco Donatelli, Maurizio Tespili, Carlo Banfi, Francesco Casilli, Daniele Cosseta, Antonio Miceli, Silvia Cirri, Federico Pappalardo   +10 more
doaj   +1 more source

Giant cell myocarditis masquerading as orbital myositis with a rapid, fulminant course necessitating mechanical support and heart transplantation. [PDF]

, 2017
Giant cell myocarditis (GCM), a rapidly progressive inflammation of the myocardium, is associated with fulminant heart failure, refractory ventricular arrhythmias, and conduction system abnormalities.
Aksoy, Olcay, Ardehali, Reza, Garg, Vinisha, Huynh, Tracy, Shah, Janki, Tan, Weiyi   +5 more
core   +1 more source

Enhanced recovery from fulminant myocarditis by treatment with the combined use of the Impella left ventricular assist device with extracorporeal membrane oxygenation: a case series

JA Clinical Reports, 2022
Background We experienced two adult cases of fulminant myocarditis with severe cardiogenic shock where Impella left ventricular assist device [left ventricle (LV)-Impella] was concomitantly used with venoarterial extracorporeal membrane oxygenation (V-A ...
Hideyuki Nandate, Tasuku Nishihara, Yukihiro Nakata, Taisuke Hamada, Yasushi Takasaki, Toshihiro Yorozuya   +5 more
doaj   +1 more source

Complete Revascularisation in Impella-Supported Infarct-Related Cardiogenic Shock Patients Is Associated With Improved Mortality

Frontiers in Cardiovascular Medicine, 2021
Background: Acute myocardial infarction-related cardiogenic shock (AMI-CS) still has high likelihood of in-hospital mortality. The only trial evidence currently available for the intra-aortic balloon pump showed no benefit of its routine use in AMI-CS ...
Andreas Schäfer, Ralf Westenfeld, Jan-Thorben Sieweke, Andreas Zietzer, Julian Wiora, Giulia Masiero, Carolina Sanchez Martinez, Giuseppe Tarantini, Nikos Werner, Nikos Werner   +9 more
doaj   +1 more source

IABP versus Impella Support in Cardiogenic Shock: “In Silico” Study

Journal of Cardiovascular Development and Disease, 2023
Cardiogenic shock (CS) is part of a clinical syndrome consisting of acute left ventricular failure causing severe hypotension leading to inadequate organ and tissue perfusion.
Beatrice De Lazzari, Massimo Capoccia, Roberto Badagliacca, Selim Bozkurt, Claudio De Lazzari   +4 more
doaj   +1 more source

Surgical embolectomy for acute massive pulmonary embolism: state of the art [PDF]

, 2018
Massive pulmonary embolism (PE) is a severe condition that can potentially lead to death caused by right ventricular (RV) failure and the consequent cardiogenic shock.
De Bellis, Antonio, D’Abramo, Mizar, Frati, Giacomo, Greco, Ernesto, Iaccarino, Alessandra, Iovine, Elio, Saade, Wael, Schirone, Leonardo, Sciarretta, Sebastiano   +8 more
core   +1 more source